drugset / Trial / NCT00250354

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

NCT00250354

Phase 3 Completed 110 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild, moderate, or borderline mental retardation.

Timeline

Start
1997-09
Primary completion
Completion
1999-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.06 mg/kg Oral